Pub Date : 2021-05-19DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251
M. Miravitlles, P. Calverley, K. Verhamme, M. Dreher, V. Bayer, A. Gardev, A. Hoz, J. Wedzicha, D. Price
Introduction : A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to-severe COPD and predominantly lower exacerbation risk. Methods : Patients who received either LAMA+LABA+ICS (n=11,891) or LAMA+LABA (n=3,156) were pooled from phase 3/4 randomized controlled trials (TONADO 1/2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR). Analysis was on-treatment and censored at 52 weeks. Propensity score (PS)-matched cohorts (covariates: age, sex, Conclusions : This pooled analysis showed no differences in mortality between LAMA+LABA and LAMA+LABA+ICS in patients with moderate-to-severe COPD and predominantly lower exacerbation risk.
{"title":"A Pooled Analysis of Mortality in Patients with COPD Receiving Triple Therapy versus Dual Bronchodilation","authors":"M. Miravitlles, P. Calverley, K. Verhamme, M. Dreher, V. Bayer, A. Gardev, A. Hoz, J. Wedzicha, D. Price","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2251","url":null,"abstract":"Introduction : A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to-severe COPD and predominantly lower exacerbation risk. Methods : Patients who received either LAMA+LABA+ICS (n=11,891) or LAMA+LABA (n=3,156) were pooled from phase 3/4 randomized controlled trials (TONADO 1/2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR). Analysis was on-treatment and censored at 52 weeks. Propensity score (PS)-matched cohorts (covariates: age, sex, Conclusions : This pooled analysis showed no differences in mortality between LAMA+LABA and LAMA+LABA+ICS in patients with moderate-to-severe COPD and predominantly lower exacerbation risk.","PeriodicalId":169302,"journal":{"name":"TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130382972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-01DOI: 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2261
P. Lenga, C. Grah, C. Ruwwe-Glösenkamp, J. Saccomanno, S. Eggeling, J. Pfannschmidt, S. Gläser, S. Kurz, G. Lesschber, J. Rückert, B. Schmidt, P. Schneider, R. A. Gebhardt, A. Gebhardt, B. Becke, O. Schega, A. Holland, A. Kirschbaum, S. Eisenmann, M. Krüger, R. Hübner
{"title":"Outcome of Surgical and Endoscopic Lung Volume Reduction with Valves in Patients with Severe Lung Emphysema: Preliminary Results from the National Lung Emphysema Registry (LE-R) in Germany","authors":"P. Lenga, C. Grah, C. Ruwwe-Glösenkamp, J. Saccomanno, S. Eggeling, J. Pfannschmidt, S. Gläser, S. Kurz, G. Lesschber, J. Rückert, B. Schmidt, P. Schneider, R. A. Gebhardt, A. Gebhardt, B. Becke, O. Schega, A. Holland, A. Kirschbaum, S. Eisenmann, M. Krüger, R. Hübner","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2261","DOIUrl":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2261","url":null,"abstract":"","PeriodicalId":169302,"journal":{"name":"TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134391843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：